Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity

Claudia Koch, Andra Kuske, Simon A. Joosse, Gökhan Yigit, George Sflomos, Sonja Thaler, Daniel J. Smit, Stefan Werner, Kerstin Borgmann, Sebastian Gärtner, Parinaz Mossahebi Mohammadi, Laura Battista, Laure Cayrefourcq, Janine Altmüller, Gabriela Salinas-Riester, Kaamini Raithatha, Arne Zibat, Y. Goy, Leonie Ott, Kai Bartkowiak, Tuan Zea Tan, Qing Zhou, Michael R. Speicher, Volkmar Müller, Tobias M. Gorges, Manfred Jücker, Jean Paul Thiery, Cathrin Brisken, Sabine Riethdorf, Catherine Alix‐Panabières, Klaus PantelEMBO 2020 · DOI

TL;DR

Researchers have successfully established and characterized a novel cell line, CTC-ITB-01, derived from circulating tumor cells (CTCs) of a patient with metastatic estrogen receptor-positive (ER+) breast cancer. This cell line retains key characteristics of the original CTCs and exhibits tumorigenic and metastatic potential, offering a valuable new model for studying CTC biology and developing targeted therapies.

What Problem Does This Paper Address?

Circulating tumor cells (CTCs) are shed from primary tumors into the bloodstream and can seed distant metastases, a major cause of cancer-related death. While CTCs hold immense potential for early detection, monitoring, and personalized treatment, studying their functional properties has been severely hampered by their extremely low abundance in patient blood and the lack of suitable in vitro models. Existing cell lines often don't accurately reflect the characteristics of CTCs found in patients, making it difficult to understand their biology, particularly their ability to survive, extravasate, and form new tumors. This paper addresses this critical gap by developing and characterizing a novel, functional cell line directly derived from patient CTCs.

Methods

The researchers employed a multi-faceted approach:

  • CTC Isolation and Cultivation: CTCs were enriched from patient blood using the CellSearch® system and then cultured using a RosetteSep™ technology to minimize phenotype bias. This led to the establishment of the CTC-ITB-01 cell line.
  • Genomic Analysis: Copy Number Aberration (CNA) profiling and Whole Exome Sequencing (WES) were performed on the CTC line, primary tumors, and metastasis to compare their genetic landscapes. Hierarchical clustering was used to assess the similarity of CNA profiles.
  • Molecular Characterization: RNA sequencing was used for expression-based subtyping (PAM50 and scmod2 classifiers). Western blotting and immunocytochemistry were used to assess protein expression (e.g., ER, ERBB2, epithelial/mesenchymal markers, stemness markers).
  • Functional Assays:
    • In vitro growth assays: Tested the response to estrogen and the CDK4/6 inhibitor Palbociclib.
  • Epithelial-Mesenchymal Transition (EMT) scoring: Analyzed RNA-sequencing data to quantify the degree of EMT.
  • Fluoro-EPISPOT assays: Assessed the secretion of specific proteins.
  • ALDH activity measurement: Evaluated cancer stem cell properties via flow cytometry.
  • In vivo Xenograft Model: GFP-luciferase tagged CTC-ITB-01 cells were injected into the mammary ducts of immunodeficient mice (NSG model) to assess tumorigenic and metastatic potential. Bioluminescence imaging and histological analysis were used for monitoring.

Datasets

  • Patient-derived CTCs: Blood samples from a patient with metastatic ER+ breast cancer were used to establish the CTC-ITB-01 cell line.
  • Primary tumors and metastasis: Tissue samples from the same patient's primary tumors and vaginal metastasis were used for comparative genomic analysis.
  • Established cell lines: MCF-7 (ER+ breast cancer cell line) and Hs578t (mesenchymal ER- breast cancer cell line) were used as controls for Western blot analysis. A549 cells were used as a positive control for ALDH activity.
  • Publicly available data: RNA-sequencing data from clinical samples and established cell lines were used for EMT scoring (Tan et al., 2014).

Key Insights and Ideas

  • CTC Line Stability: The CTC-ITB-01 line maintained high concordance in CNA profiles with the original patient CTCs, suggesting minimal genomic drift during culture and making it a representative model.
  • Constitutive ER Signaling: Downstream ER signaling in CTC-ITB-01 cells was constitutively active, independent of estrogen ligand availability. This is a crucial finding that could explain resistance to endocrine therapy.
  • EMT Plasticity: The CTC-ITB-01 cells exhibited a heterogeneous morphology and demonstrated characteristics of epithelial-mesenchymal plasticity, with both adherent and non-adherent growth patterns. Despite this plasticity, EMT scoring indicated a predominantly epithelial phenotype.
  • Cancer Stem Cell Features: The cell line displayed characteristics of cancer stem cells, including high ALDH activity and CD44+/CD24+ expression, suggesting a role for stemness in their aggressive behavior.
  • Therapeutic Vulnerability: Despite resistance to endocrine therapy, CTC-ITB-01 cells were highly sensitive to the CDK4/6 inhibitor Palbociclib, indicating a potential therapeutic avenue for patients with similar tumors.
  • In Vivo Tumorigenicity and Metastasis: The CTC-ITB-01 cells successfully formed primary tumors and metastasized to clinically relevant organs (bone, liver, brain, lung) in a mouse model, mirroring the patient's disease progression.

Key Results

  • A novel ER+ breast cancer CTC line, CTC-ITB-01, was successfully established and characterized.
  • Genomic analysis showed high concordance between CTC-ITB-01 and patient-derived CTCs, with distinct CNA profiles compared to primary tumors and metastasis, suggesting tumor evolution.
  • CTC-ITB-01 cells maintained ER+ status and exhibited a predominantly epithelial gene expression signature.
  • The cell line demonstrated tumorigenic potential and metastatic capacity in an intraductal PDX mouse model, recapitulating clinical progression.
  • CTC-ITB-01 cells showed constitutive ER signaling and were significantly inhibited by Palbociclib (IC50 = 0.21 µM), comparable to MCF-7 cells (IC50 = 0.13 µM).
  • The cell line exhibited cancer stem cell markers (ALDH+) and phenotypic plasticity.

Limitations and Future Work

  • Limited Patient Cohort: The cell line was derived from a single patient, limiting generalizability. Future work should involve establishing and characterizing CTC lines from a larger, more diverse patient cohort.
  • In Vitro vs. In Vivo Drug Response: While in vitro drug testing showed sensitivity to Palbociclib, further in vivo xenotransplantation studies are needed to confirm these findings and assess therapeutic efficacy in a more complex biological system.
  • Mechanisms of Resistance: The paper notes that CTC-ITB-01 cells are resistant to endocrine therapy but do not harbor ESR1 mutations, suggesting alternative resistance mechanisms that warrant further investigation.
  • EMT and Stemness Complexity: While the study provides evidence for EMT plasticity and stem cell features, further detailed investigations are required to fully elucidate the role of these programs in CTC survival and metastasis.
  • Microenvironment Interaction: The study focuses on intrinsic CTC properties. Future research could explore how CTC-ITB-01 cells interact with different microenvironments to better understand metastasis.

Summary updated

Abstract

Functional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency of CTCs and lack of appropriate models. Here, we describe the characterization of a novel CTC-derived breast cancer cell line, designated CTC-ITB-01, established from a patient with metastatic estrogen receptor-positive (ER<sup>+</sup> ) breast cancer, resistant to endocrine therapy. CTC-ITB-01 remained ER<sup>+</sup> in culture, and copy number alteration (CNA) profiling showed high concordance between CTC-ITB-01 and CTCs originally present in the patient with cancer at the time point of blood draw. RNA-sequencing data indicate that CTC-ITB-01 has a predominantly epithelial expression signature. Primary tumor and metastasis formation in an intraductal PDX mouse model mirrored the clinical progression of ER<sup>+</sup> breast cancer. Downstream ER signaling was constitutively active in CTC-ITB-01 independent of ligand availability, and the CDK4/6 inhibitor Palbociclib strongly inhibited CTC-ITB-01 growth. Thus, we established a functional model that opens a new avenue to study CTC biology.
BibTeX
@inproceedings{koch2020characterization,
  author = {Claudia Koch and Andra Kuske and Simon A. Joosse and Gökhan Yigit and George Sflomos and Sonja Thaler and Daniel J. Smit and Stefan Werner and Kerstin Borgmann and Sebastian Gärtner and Parinaz Mossahebi Mohammadi and Laura Battista and Laure Cayrefourcq and Janine Altmüller and Gabriela Salinas-Riester and Kaamini Raithatha and Arne Zibat and Y. Goy and Leonie Ott and Kai Bartkowiak and Tuan Zea Tan and Qing Zhou and Michael R. Speicher and Volkmar Müller and Tobias M. Gorges and Manfred Jücker and Jean Paul Thiery and Cathrin Brisken and Sabine Riethdorf and Catherine Alix‐Panabières and Klaus Pantel},
  title = {{Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity}},
  booktitle = {EMBO},
  year = {2020},
  doi = {10.15252/emmm.201911908},
}
Figure